

James A Karlowsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3324304/publications.pdf>

Version: 2024-02-01

130
papers

5,480
citations

87888

38
h-index

91884

69
g-index

132
all docs

132
docs citations

132
times ranked

4846
citing authors

#	ARTICLE	IF	CITATIONS
1	Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem- β -Lactamase Inhibitor Combinations. <i>Drugs</i> , 2018, 78, 65-98.	10.9	291
2	Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , 2019, 79, 271-289.	10.9	274
3	Review of Macrolides and Ketolides. <i>Drugs</i> , 2001, 61, 443-498.	10.9	249
4	Antimicrobial-Resistant Pathogens in Intensive Care Units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1430-1437.	3.2	207
5	Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. <i>Drugs</i> , 2016, 76, 567-588.	10.9	199
6	<i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	187
7	<i>In Vitro</i> Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	159
8	A Canadian National Surveillance Study of Urinary Tract Isolates from Outpatients: Comparison of the Activities of Trimethoprim-Sulfamethoxazole, Ampicillin, Mecillinam, Nitrofurantoin, and Ciprofloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1089-1092.	3.2	148
9	Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008). <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4684-4693.	3.2	138
10	<i>In Vitro</i> Susceptibility of Global Surveillance Isolates of <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam (INFORM 2012 to 2014). <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4743-4749.	3.2	132
11	Molecular epidemiology of extended-spectrum β -lactamase-, AmpC β -lactamase- and carbapenemase-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, i57-i65.	3.0	131
12	<i>In Vitro</i> Activity of Aztreonam-Avibactam against Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	129
13	<i>In Vitro</i> Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 456-466.	2.5	119
14	<i>In Vitro</i> Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance) <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 61, 1077-1082.	3.2	107
15	Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, i7-i22.	3.0	114
16	<i>In Vitro</i> Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	102
17	Antimicrobial Resistance in Urinary Tract Pathogens in Canada from 2007 to 2009: CANWARD Surveillance Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3169-3175.	3.2	97
18	Prevalence of Antimicrobial Resistance among Clinical Isolates of <i>Bacteroides fragilis</i> Group in Canada in 2010-2011: CANWARD Surveillance Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1247-1252.	3.2	89

#	ARTICLE	IF	CITATIONS
19	Prevalence of Antimicrobial Resistance in Respiratory Tract Isolates of <i>Streptococcus pneumoniae</i> : Results of a Canadian National Surveillance Study. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2504-2509.	3.2	88
20	<i>In Vitro</i> Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1638-1649.	3.9	77
21	AFN-1252, a FabI Inhibitor, Demonstrates a <i>Staphylococcus</i> -Specific Spectrum of Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3544-3548.	3.2	71
22	Telavancin: Mechanisms of Action, <i>In Vitro</i> Activity, and Mechanisms of Resistance. <i>Clinical Infectious Diseases</i> , 2015, 61, S58-S68.	5.8	71
23	<i>In vitro</i> activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1872-1879.	3.0	68
24	Characterization of MDR and XDR <i>Streptococcus pneumoniae</i> in Canada, 2007-13. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2199-2202.	3.0	65
25	Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible <i>Enterobacteriales</i> Collected as Part of a Global Surveillance Program, 2012 to 2017. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0200020.	3.2	61
26	<i>In vitro</i> activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 55-62.	1.8	60
27	Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. <i>Drugs</i> , 2020, 80, 285-313.	10.9	60
28	Fidaxomicin: A Novel Agent for the Treatment of <i>Clostridium difficile</i> Infection. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2015, 26, 305-312.	1.9	59
29	Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2016, 2016, 1-10.	1.9	58
30	Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 321-325.	1.8	57
31	Microbiology and Preclinical Review of Omadacycline. <i>Clinical Infectious Diseases</i> , 2019, 69, S6-S15.	5.8	55
32	Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015. <i>Journal of Medical Microbiology</i> , 2017, 66, 61-69.	1.8	53
33	Evaluation of three MALDI-TOF mass spectrometry libraries for the identification of filamentous fungi in three clinical microbiology laboratories in Manitoba, Canada. <i>Mycoses</i> , 2018, 61, 743-753.	4.0	50
34	<i>In Vitro</i> Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	50
35	Analysis of multidrug resistance in the predominant <i>Streptococcus pneumoniae</i> serotypes in Canada: the SAVE study, 2011-15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii12-vii19.	3.0	48
36	42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv5-iv21.	3.0	43

#	ARTICLE	IF	CITATIONS
37	In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples â€“ SMART Surveillance Europe 2015â€“2017. <i>Journal of Medical Microbiology</i> , 2020, 69, 207-217.	1.8	43
38	In Vitro Activity of Fosfomycin against Escherichia coli Isolated from Patients with Urinary Tract Infections in Canada as Part of the CANWARD Surveillance Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1252-1256.	3.2	42
39	Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013â€“2015. <i>Brazilian Journal of Infectious Diseases</i> , 2017, 21, 343-348.	0.6	41
40	Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, i47-i55.	3.0	40
41	In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 â€“ Results from the SMART global surveillance program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 171-176.	1.8	39
42	Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015â€“2016. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 15, 140-147.	2.2	39
43	Evaluation of Five Chromogenic Agar Media and the Rosco Rapid Carb Screen Kit for Detection and Confirmation of Carbapenemase Production in Gram-Negative Bacilli. <i>Journal of Clinical Microbiology</i> , 2015, 53, 105-112.	3.9	38
44	Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2016, 76, 1737-1757.	10.9	38
45	In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015â€“2017. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 223-228.	2.2	37
46	Antimicrobial susceptibility of 2906 Pseudomonas aeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008â€“2015. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 87, 60-63.	1.8	36
47	Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv64-iv71.	3.0	36
48	In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 97, 115012.	1.8	36
49	In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 174-177.	2.5	34
50	Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015â€“17. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2284-2288.	3.0	34
51	In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007â€“2009 study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 342-347.	1.8	31
52	Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2018, 2018, 1-13.	1.9	31
53	Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 375-379.	2.5	29
54	Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011â€“15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii20-vii31.	3.0	27

#	ARTICLE	IF	CITATIONS
55	Species distribution and antifungal susceptibility of invasive <i>Candida</i> isolates from Canadian hospitals: results of the CANWARD 2011-16 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv48-iv54.	3.0	27
56	Screening of Stool Samples for Identification of Vancomycin-Resistant Enterococcus Isolates Should Include the Methyl- β -D-Glucopyranoside Test To Differentiate Nonmotile Enterococcus gallinarum from <i>E. faecium</i> . <i>Journal of Clinical Microbiology</i> , 1998, 36, 2333-2335.	3.9	27
57	Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant <i>Escherichia coli</i> . <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2018, 2018, 1-9.	1.9	26
58	Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 645-653.	3.0	26
59	In-vitro activity of imipenem/relebactam and key β -lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105841.	2.5	26
60	Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant <i>Streptococcus pneumoniae</i> : analysis of Phase 3 clinical trial data. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2835-2840.	3.0	25
61	In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β -lactamase (ESBL)-positive isolates of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolated from hospitalized patients (SMART 2016). <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114925.	1.8	25
62	Frequency of MCR-1-mediated colistin resistance among <i>Escherichia coli</i> clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015). <i>CMAJ Open</i> , 2016, 4, E641-E645.	2.4	24
63	Comparison of commercial assays and laboratory developed tests for detection of SARS-CoV-2. <i>Journal of Virological Methods</i> , 2020, 285, 113970.	2.1	24
64	Empyema Caused by <i>Clostridium bifermentans</i> : A Case Report. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2015, 26, 105-107.	1.9	23
65	PCR ribotyping and antimicrobial susceptibility testing of isolates of <i>Clostridium difficile</i> cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian <i>Clostridium difficile</i> Surveillance Study (CAN-DIFF) 2013-2015. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 105-111.	1.8	23
66	Characterization of carbapenem-resistant and XDR <i>Pseudomonas aeruginosa</i> in Canada: results of the CANWARD 2007-16 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv32-iv38.	3.0	23
67	Prevalence of ESBL non-CRE <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106535.	2.5	22
68	In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible <i>Pseudomonas aeruginosa</i> clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 703-708.	3.0	21
69	Comparison of antimicrobial resistance patterns in <i>Streptococcus pneumoniae</i> from respiratory and blood cultures in Canadian hospitals from 2007-16. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv39-iv47.	3.0	21
70	Activity of imipenem-relebactam against multidrug-resistant <i>Pseudomonas aeruginosa</i> from the United States - SMART 2015-2017. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 95, 212-215.	1.8	21
71	In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	20
72	Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2021, 81, 233-256.	10.9	20

#	ARTICLE	IF	CITATIONS
73	Isolation of multiple carbapenemase-producing Gram-negative bacilli from a patient recently hospitalized in Nigeria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 296-298.	1.8	19
74	Characterization of MRSA in Canada from 2007 to 2016. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv55-iv63.	3.0	19
75	<i>In Vitro</i> Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	19
76	Antimicrobial susceptibility testing of invasive isolates of <i>Streptococcus pneumoniae</i> from Canadian patients: the SAVE study, 2011-2015. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii5-vii11.	3.0	17
77	Real-life experience with ceftobiprole in Canada: Results from the CLEAR (Canadian Leadership in Antibiotic Resistance) Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 73, 1000-1007.	2.2	17
78	<i>In Vitro</i> activities of Tedizolid and comparator antimicrobial agents against clinical isolates of <i>Staphylococcus aureus</i> collected in 12 countries from 2014 to 2016. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 151-157.	1.8	15
79	Antimicrobial susceptibility of <i>Clostridioides difficile</i> isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian <i>Clostridioides difficile</i> (CAN-DIFF) surveillance study from 2013 to 2017. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1824-1832.	3.0	15
80	<i>In vitro</i> susceptibility of urinary <i>Escherichia coli</i> isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 62-68.	2.5	14
81	Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2020, 2020, 1-11.	1.9	12
82	Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. <i>Drugs</i> , 2022, 82, 533-557.	10.9	12
83	Carbapenem-resistant Enterobacterales and <i>Pseudomonas aeruginosa</i> causing infection in Africa and the Middle East: a surveillance study from the ATLAS programme (2018-2020). <i>JAC-Antimicrobial Resistance</i> , 2022, 4, .	2.1	12
84	<i>In Vitro</i> Activity of Ceftazidime-Avibactam against 338 Molecularly Characterized Gentamicin-Nonsusceptible Gram-Negative Clinical Isolates Obtained from Patients in Canadian Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3623-3626.	3.2	10
85	<i>In vitro</i> activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 87, 349-356.	1.8	10
86	<i>In vitro</i> activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD) Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 73, 1000-1007.	2.0	10
87	<i>In vitro</i> activity of ceftazidime-avibactam against Enterobacterales and <i>Pseudomonas aeruginosa</i> isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101647.	0.6	10
88	Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007-2019. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlab197.	2.1	10
89	Osteomyelitis Due to Multiple Carbapenemase-Producing Gram-Negative Bacteria: The First Case Report of a GES-13-Producing <i>Pseudomonas aeruginosa</i> isolate in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2014, 25, 229-231.	1.9	9
90	Identification and Characterization of a Novel FosA7 Member from Fosfomycin-Resistant <i>Escherichia coli</i> Clinical Isolates from Canadian Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	9

#	ARTICLE	IF	CITATIONS
91	In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	9
92	<i>In Vitro</i> Activity of Cefiderocol against Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> : CANWARD, 2007 to 2019. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	9
93	An Unusual Case of <i>Streptococcus anginosus</i> Group Pyomyositis Diagnosed Using Direct 16S Ribosomal DNA Sequencing. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2014, 25, 32-34.	1.9	8
94	Susceptibility of Clinical Isolates of <i>Escherichia coli</i> to Fosfomycin as Measured by Four <i>In Vitro</i> Testing Methods. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	8
95	ESBL-positive <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates from across Canada: CANWARD surveillance study, 2007–18. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2815-2824.	3.0	8
96	In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and <i>Pseudomonas aeruginosa</i> isolated from patients across Canada as part of the CANWARD study, 2016-2019. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115418.	1.8	8
97	Determination of Disk Diffusion and MIC Quality Control Ranges for Nafithromycin (WCK 4873), a New Lactone-Ketolide. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3021-3027.	3.9	7
98	Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 99, 115282.	1.8	7
99	In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015–2018. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 249-256.	2.2	7
100	Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38 25, 346-350.	2.2	7
101	Use of Fosfomycin Etest To Determine <i>In Vitro</i> Susceptibility of Clinical Isolates of Enterobacterales Other than <i>Escherichia coli</i> , Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0163521.	3.9	7
102	Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011–2018. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115447.	1.8	7
103	Evaluation of MRSA Select ⁺ Chromogenic Medium for the Early Detection of Methicillin-Resistant <i>Staphylococcus aureus</i> from Blood Cultures. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2013, 24, e113-e116.	1.9	6
104	Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus <i>Escherichia coli</i> using an in vitro model. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 271-275.	1.8	6
105	Whole genome characterization of <i>Streptococcus pneumoniae</i> from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007–2018. <i>Vaccine</i> , 2021, 39, 5474-5483.	3.8	6
106	Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 30, 23-30.	2.2	6
107	Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant <i>Streptococcus pneumoniae</i> : analysis of Phase 3 clinical trial data—authors' response: Figure 1.. <i>Journal of Antimicrobial Chemotherapy</i> . 2015. 70. 3170.2-3171.	3.0	5
108	CHROMagar ⁺ orientation urine culture medium produces matrix-assisted laser desorption ionization–time-of-flight mass spectrometry spectra misidentified as <i>Mycoplasma arginini</i> and <i>Mycoplasma alkalescens</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 113-115.	1.8	5

#	ARTICLE	IF	CITATIONS
109	Ciprofloxacin or Imipenem Use Correlates with Resistance in <i>Pseudomonas aeruginosa</i> . Canadian Journal of Infectious Diseases & Medical Microbiology, 1998, 9, 382-386.	0.3	4
110	Clinical utility of echocardiography for the diagnosis of native valve infective endocarditis in <i>Staphylococcus aureus</i> bacteremia. Echocardiography, 2019, 36, 1852-1858.	0.9	4
111	Frequency of 16S ribosomal RNA methyltransferase detection among <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013-2017). Diagnostic Microbiology and Infectious Disease, 2019, 94, 199-201.	1.8	4
112	Report of a KPC-producing <i>Pseudomonas aeruginosa</i> isolate in Canada. Journal of Antimicrobial Chemotherapy, 2019, 74, 1748-1749.	3.0	4
113	Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing <i>Escherichia coli</i> collected from Canadian hospitals: CANWARD 2007-18. Journal of Antimicrobial Chemotherapy, 2021, 76, 2825-2832.	3.0	4
114	Kisameet Clay Isolated from the Central Coast of British Columbia, Canada, Demonstrates Broad-Spectrum Antimicrobial Activity. MBio, 2016, 7, e00169.	4.1	3
115	Analysis of Potential β -Lactam Surrogates To Predict <i>In Vitro</i> Susceptibility and Resistance to Ceftriaxone for Clinical Isolates of Enterobacteriaceae. Journal of Clinical Microbiology, 2018, 56, .	3.9	3
116	Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, 2021, 1-7.	1.9	3
117	Analysis of 1560 Inpatient and Outpatient <i>Escherichia coli</i> isolates from across Canada-Results from the CANWARD 2007 Study. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, 49A-53A.	1.9	2
118	Failure of a multiplex polymerase chain reaction assay to detect IMP-27 in a clinical isolate of <i>Morganella morganii</i> . Diagnostic Microbiology and Infectious Disease, 2018, 92, 194-195.	1.8	2
119	Fosfomycin resistance mediated by <i>fos</i> genes remains rare among extended-spectrum beta-lactamase-producing <i>Escherichia coli</i> clinical isolates recovered from the urine of patients evaluated at Canadian hospitals (CANWARD, 2007-2017). Diagnostic Microbiology and Infectious Disease. 2020. 96. 114962.	1.8	2
120	PCV-15 and PPSV-23 coverage of invasive and respiratory tract <i>Streptococcus pneumoniae</i> , including MDR and XDR isolates: CANWARD 2007-20. Journal of Antimicrobial Chemotherapy, 2022, 77, 1444-1451.	3.0	2
121	Cefotaxime susceptibility should not be used to predict ceftriaxone susceptibility among <i>Klebsiella oxytoca</i> clinical isolates. Journal of Global Antimicrobial Resistance, 2020, 21, 270-271.	2.2	1
122	Evaluation of the Hologic Aptima Combo 2 Assay for Detection of <i>Neisseria gonorrhoeae</i> from Joint Fluid Specimens. Journal of Clinical Microbiology, 2022, 60, e0253021.	3.9	1
123	In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 <i>Pseudomonas aeruginosa</i> Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013. Open Forum Infectious Diseases, 2014, 1, S109-S109.	0.9	0
124	In Vitro Activity of Newer Antimicrobials and Relevant Comparators Vs. 349 <i>Stenotrophomonas maltophilia</i> Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011-2016). Open Forum Infectious Diseases, 2017, 4, S367-S368.	0.9	0
125	In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible <i>Pseudomonas aeruginosa</i> Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008-2016. Open Forum Infectious Diseases, 2017, 4, S372-S372.	0.9	0
126	2383. <i>In Vitro</i> Activity of Ceftolozane-Tazobactam in Comparison With Ceftazidime-Avibactam vs. Antimicrobial Non-Susceptible <i>Pseudomonas aeruginosa</i> Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007-2017. Open Forum Infectious Diseases, 2018, 5, S710-S710.	0.9	0

#	ARTICLE	IF	CITATIONS
127	Answer to November 2019 Photo Quiz. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	0
128	Absence of transmission of NDM and OXA-48 carbapenemase genes in a chronic care unit of a long-term care facility. <i>Journal of Infection Prevention</i> , 2022, 23, 15-19.	0.9	0
129	In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin. <i>Jammi</i> , 2021, 6, 149-162.	0.5	0
130	Photo Quiz: A 59-Year-Old Male with Nodular Cutaneous Lesions. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	0